Florida Cancer Specialists & Research Institute has experts who administer the latest and most advanced treatments for cancer available within the communities where their patients live.
Florida Cancer Specialists & Research Institute (FCS) is intentional in bringing world-class oncology and hematology care to patients. To make this possible, our physicians, experts in administering the latest and most advanced treatments for cancer, are available within the communities where our patients live.
FCS sets the gold standard for community oncology. Our primary purpose – and our passion – is to provide convenient access to the most advanced cancer treatments, encompassing innovative clinical research, cutting-edge technologies, targeted therapies, genomic-based treatment, and immunotherapy.
Our state-of-the-art facilities incorporate evidence-based design to maximize provider efficiencies and create a patient care environment that reduces stress and aids in achieving optimal outcomes.
Centralized clinical ancillaries are seamlessly integrated into patient care, with ready access to diagnostic imaging, centralized pathology laboratory and in-house specialty pharmacy, radiation and interventional radiology, and 24/7 care management.
Across our practice we provide hereditary counseling, supportive care, oncology nutrition, and behavioral health therapies to help ease stress for patients and families and improve their overall quality of life.
As our footprint expands into new markets, we welcome such talented individuals to explore a medical career at FCS. Our physicians have access to a network of 250+ physician peers with resources such as clinical trials, advanced therapies and innovative testing and technology at their fingertips.
Consider one of these exciting opportunities today: https://flcancer.com/physician-opportunities/.
Petosemtamab and Pembrolizumab: A Promising Pair in HNSCC Treatment
July 2nd 2024In an interview, Cesar Augusto Perez, MD, delved into the findings from a phase 2 study evaluating petosemtamab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Read More